Recent guidelines in the clinical management of HIV infection suggest testing for drug resistance is an integral part of antiretroviral therapy (ART). However, tests of antiretroviral (ARV) drug resistance, which measure the susceptibility of a patient's virus to current ARV medications, come in a variety of flavors, such as genotype, phenotype, and virtual phenotype. Once results are returned, there is a wide array of interpretation systems and algorithms to guide ART. Susceptibility testing provides a way to estimate sensitivity or resistance of HIV-1 to each of the 20 currently licensed ARV medications.
Clinical HIV drug resistance may be defined as persistent active infection, measured as plasma viremia, despite adequate drug exposure. Despite drug resistance, beneficial clinical virologic responses, with a reduction in plasma viremia and an increase in CD4 cells, may be achieved. Susceptibility testing, which can identify viral correlates of clinical resistance, can guide different treatment choices.
Applying the journalist's paradigm -"who, what, when, where, and why"-to susceptibility testing may provide a framework to consider whether testing leads to an improvement in outcome of therapy. How can the results of susceptibility testing be used more effectively in the management of ART? Genotypic and phenotypic susceptibility testing is becoming more complex and interpretation more sophisticated. Who will benefit from testing, and when should susceptibility be tested? How to interpret resistance has focused on evidence from specific types of tests.
As a brief introduction to the uses and interpretation of susceptibility testing, it is important to remember that the information is limited to genotypic or phenotypic features of a patient's viremia. These are the currently replicating viruses, which predominate plasma viremia. Genotypic tests identify the consensus sequence of reverse transcriptase (RT) and protease genes from plasma virus, and the primary and secondary mutations, or patterns of mutations that are associated with drug resistance. 1 Most of the phenotyping is limited to results from the commercial suppliers, ViroLogic and Virco. These tests measure the plasma virus susceptibility to drugs through rounds of replication in the presence of varying amounts of drug. Results for each drug are presented as 50 percent inhibitory concentration measurement (IC 50 ), which is the drug concentration inhibiting viral replication by 50 percent, as measured by p24 antigen production or RT activity in an in vitro system. The IC 50 is then expressed as "fold change" as compared to a "wild-type" or control isolate. The "virtual phenotype" is a specific commercial service offered by Tibotec-Virco, which uses the information from genotyping, combined with a proprietary database of more than 20,000 genotype-phenotype correlations to predict phenotype from genetic sequence.
The evidence for a clinical benefit of susceptibility testing is based on randomized controlled trials. Various types of resistance testing with or without expert advice, and algorithms for prescribing new drugs have been compared to physician-selected or standard-of-care treatment. 1, 11 Further insight into the interpretation and role of testing may be gained through retrospective analyses of genotypic and phenotypic resistance testing in the context of treatment and trials. 12, 18 Recent information on the increasing frequency and persistence of resistance transmitted in primary infections has led to new recommendations for testing in this context. 20, 23 There are several questions in the practical management of ART: Which kinds of resistance testing are available, why obtain this information, and how can it be used to improve antiretroviral treatment efficiency?
As more becomes known about the mechanisms of resistance, and larger databases of mutations, phenotype, and treatment outcomes are accrued, there are increasing methods to identify, and then interpret drug susceptibility. 24, 30 Genotypic interpretations are expert systems of rules-based algorithms, 24, 27 and virtual phenotype indicates whether a virus is sensitive, intermediate, or resistant. These systems estimate the predicted fold change in phenotype susceptibility related to genotype. The results of several of the initial randomized control trials, comparing resistance testing to physician-guided or standard-of-care changes in regimens, are illustrated in Figure 1 . The metric by which these may be compared -the mean log copy number difference between the resistance testing group, and whether it was genotype or phenotype, and the standard-of-care or the physician-guided groupshowed an average of about a third of a log (50 percent) reduction in RNA at 12 to 24 weeks. There was very limited evidence of a difference in durable antiviral activity that could be discerned in these studies, based on modest differences in RNA levels at 12 to 24 weeks.
Retrospective phenotypic testing predicted durable virologic response based on identifying the number of active drugs, or a phenotypic susceptibility score (PSS). 5, 11 The Narval 5 and Vira 3003 studies identify some subgroups who appear to benefit from resistance testing, predominantly those with only moderate drug exposure (first and second regimen failures), where resistance testing could identify new drugs and classes. The HAVANA study 3 may be the most interesting study of genotypic testing. Investigators independently randomized patients to "expert advice," which made a substantial difference among those with multi-drug failures, confirming that the treatment advice of a good virologist alone may be effective, even in the presence of a "bad" virus.
There has been a recent evaluation of the virtual phenotype in a study from Italy, 32, 33 comparing the "real" versus virtual phenotype, to give treatment guidance in defining a regimen for challenging heavily pre-treated patients. This study, dubbed the "genotypophenotypo in resistencia," was a carefully done trial with 48 weeks of follow-up. The outcome was a sustained suppression among approximately 100 heavily pre-treated patients in each group, comparing actual and virtual phenotype. There were no striking differences in the outcomes at 48 weeks. Twenty and 24 percent in the real and virtual groups, respectively, achieved a virus load of < 50 copies/mL of HIV RNA at 48 weeks. This may be as effective as the prescription of as many drugs as patients can tolerate-the mega-highly active antiretroviral therapy (HAART) approach. 33 The results are consistent with salvage studies of multi-regimen failure and do not support a difference between real and virtual phenotype.
There is a certain amount of convergence occurring between these competing forms of susceptibility testing. Genotypic assays may all be viewed as the construction of a "virtual" phenotype by estimating the probable drug susceptibility (phenotype) of a virus from genetic information with a variety of informatics tools. 28, 29 The evaluation of susceptibility testing includes the accuracy of genotype in predicting phenotype, or responses of patients (when resistance testing guides their treatment) as the degree and durability of the virologic and clinical responses. 6, 11, 31, 32 Finally, the likelihood of cross-resistance is an additional measure that may be derived from a genotypic susceptibility score. 34 Susceptibility testing comes into play largely in response to a decision to initiate or alter ART, which in turn is based on CD4 and RNA values, as well as the patient's clinical findings, history, and treatment adherence. Among patients on an ART regimen, monitoring of HIV RNA identifies whether a patient is virologically suppressed, or has "broken through" the ART regimen in a process depicted in Figure 2 . In the course of follow-up and management, ART is usually continued unaltered. However, if testing demonstrates viremia or the patient develops toxicity or side-effects, which will limit adherence, then generally a second HIV RNA test is obtained to confirm virologic failure. Susceptibility testing is usually performed after a "confirmed" virologic failure, and most use the threshold of repeated values on drug of more than 200 copies/mL of HIV RNA. Nevertheless, susceptibility testing may be insensitive in viremias < 1,000 copies/mL. Multiple tests may be performed as genotypes or phenotypes in the fraction of patients who experience repeated Data returned to the clinician from genotype, phenotype, or "virtual" phenotype are either the "actual susceptibility" based on a phenotype, or a virtual or estimated susceptibility from a genotype. In both cases, the plasma virus is categorized as "sensitive," "intermediate" (partial sensitivity), or "resistant" for each ARV medication. This information initiates a complex decision processwhether to add, switch, change, or modify the dosing of drugs in the antiretroviral combination. New RNA and CD4 values are obtained on the modified regimen and, depending on the outcome, the process may be repeated. The endpoint most commonly evaluated is "virus suppression," achieving "undetectable" levels of plasma viremia. These results, along with the patient's history, preferences, and past responses are used to propose a new treatment as shown in Figure 3 .
There are important limitations that apply to all resistance testing. In the interpretation of results of resistance testing, only replicating virus at the specific time point sampled is assessed. This will only identify sensitivity or resistance of the "majority" of that virus. What is expressed in the plasma at a single time may depend largely on adherence and the maintenance of effective drug levels. 35 Genotype and phenotype share some inherent limitations. These tests are not sensitive to mixtures (minority quasi-species represented at levels of < 20 percent) that may include resistant viruses, and there are complex interactions between mutations, viral fitness, and clinical outcome. Susceptibility testing augments, but does not replace an accurate drug history, careful management of ART, and good treatment adherence.
The mutations and their assigned effect on drug susceptibility do not generally take into account the interactions between mutations. These may play an important role in the rationale for continuing, replacing, or changing a specific drug in a clinical setting. Vexing problems include the diversity of methods to add the activity of three or more individual drug susceptibilities, and to estimate the effective activity of a new multi-drug regimen.
Translation of susceptibility data to develop a new treatment regimen begins with the assignment of a predicted activity for each potential drug in a regimen.
In the case of genotype, the most straightforward way of interpreting resistance from sequence may be to count and add the mutations which are known to be associated with resistance to each drug. This approach has been performed in a retrospective analysis of multiple clinical trials by Victor De Gruttola (Harvard University School of Public Health, Boston). 36 Many of the current "expert algorithms" assess sequence, identify drug resistance mutations, and provide an interpretation (sensitive, intermediate, or resistant). Recently, an increasing number of more subtle variations have been developed which include assigning weighted values to mutations with respect to drug susceptibility. 3 Genotypic algorithms are increasingly complex with large numbers of nucleic acids sequences coupled with evolving rules which differ between the systems. A probability of sensitivity or resistance is assigned for each drug. 37, 41 Drug resistance algorithms-whether for genotype, phenotype, or a virtual phenotype-may treat susceptibility as a continuum, or else as a categorical variable. A threshold or cut-off value is assigned where a drug is assumed to be completely active. Another threshold identifies complete resistance. How these cut-offs or thresholds are established, and how the values between complete sensitivity and resistance are treated can have an important effect on decisions and treatment outcome.
The identification of mutations forms a changing roadmap that evolves with our understanding of resistance. One example is the annual update provided by the International AIDS Society (IAS)-USA. This is a summary of drug resistance mutations associated with licensed ARV medications, based on expert opinion and the sum of evolving studies. 25 Robert Shafer (Stanford University, California) has reviewed 29 clinical and in vitro data used to identify resistance mutations, which can be summarized as general considerations:
■ Does this mutation appear exclusively or significantly more often in patients failing ARV medications? ■ Is the mutation associated with resistance in phenotypic tests of clinical isolates? ■ Is resistance associated with the mutation when it is introduced into laboratory strains, imparting in vitro phenotypic resistance? ■ A further less fully realized criterion is the role of empirical clinical virologic correlates. Are changes in plasma viremia in clinical trials, and in prospective and retrospective studies, associated with the selection of a specific mutation?
These observations and definitions are used to decide whether a mutation is likely to diminish the virologic activity of one or more ARV medication(s). Some of the complexities in applying susceptibility testing to clinical and virologic outcomes in patients are examined with examples from clinical studies.
Abacavir (ABC) susceptibility and resistance has been more complex than for most other nucleoside reverse transcriptase inhibitors (NRTIs). Important data were presented nearly five years ago from a GlaxoSmithKline study population of virologic responses, following the addition of ABC to the regimens of patients taking zidovudine (ZDV) and lamivudine (3TC) or Combivir.
The clinical virologic response (as a decrease in plasma viremia) was correlated with the number of thymidine analog mutations (TAMs) and the presence of the 3TCand ABC-associated M184V mutation. 43 Nearly all measures of resistance in highly experienced patients identify the M184V mutation, which usually follows exposure and virologic failure of 3TC. The initial observations of a persistent reduction in processivity of RT, and an increase in fidelity in viruses with this mutation has led to a series of clinical investigations of mutational interactions with M184V and the effect on susceptibility and resistance. The virologic correlates from the Gilead 907 study suggested that the M184V potentiates TDF activity. 37 This is an example of mutational interactions where M184V may increase susceptibility of virus to either thymidine analogs or TDF. There is additional interaction between L74V (a selected didanosine (ddI) mutation), and Y181C (a nevirapine (NVP)-induced mutation), where each of these has been shown, in vitro, to increase susceptibility to ZDV.
We approached this in the ACTG 364 patients where there was an opportunity to look at the phenotypic effect of the M184V mutation. The effect of M184V on phenotypic susceptibility to NRTIs among a highly NRTI-experienced cohort was assessed, by comparing actual phenotypes done on viruses, and whether or not they had an M184V. There was a significant decrease in ZDV and stavudine (d4T) resistance, and an increase in 3TC, ddI, and ABC resistance, depending on the presence of M184V. 44 A beneficial effect of the M184V mutation may be identified in older data where failing regimens were continued. This may be informative about the clinical virologic effects of the M184V mutation and continued use of ZDV and 3TC. In practice, NRTI combinations appeared to provide clinical and virologic benefit despite virologic failure. The first year of the NUCA 3001 study compared combinations of ZDV and 3TC, providing evidence for almost a log median reduction and an increase of several hundred CD4 cells on average, among people who were treated with these two NRTIs. 38 Follow-up data in this study have been now extended to a couple of years. Apparent interactions between M184V and TAMs, including T215Y and other TAMs, are associated with continued activity and clinical benefit of Combivir. Even after a year of treatment with ZDV monotherapy, it is still possible to see a 0.3 log (50 percent) reduction from baseline in virus load.
Relationships between resistance mutations and virologic responses are important for the interpretation of genotype with rules-based algorithms, along with expert opinion to define resistance. Rules-based algorithms result in categorization of each drug. Sensitivity, intermediate sensitivity, or resistance is validated in outcomes of prospective clinical trials that look at treatment outcomes in association with particular genotypes and treatments. One wonders how these tell us how to use genotype in the selection of effective treatments. There are more than 19 genotypic interpretation systems that use a variety of approaches-either they are rulesbased algorithms, or database comparisons as in the virtual phenotype. 30 Shafer has recently developed software that compares some of these algorithms on his database. His website (http://hivdb.stanford.edu/) provides information on patient's genotypes and the drugs that they have taken. Shafer has also developed software applicable to a sequence database that allows analysis of susceptibility, according to the rules of the analysis algorithm to obtain predicted resistance. Brun-Vezinet (A), Jo Van Damme (Rega Institute for Medical Research, Belgium), and Bayer's Visible Genetics (V) have developed interpretation systems associated with their tests and each of those algorithms, which accepts input lists of mutations and generates outputs that categorizes HIV drugs by their predicted activity. These interpretation systems, as well as the HIVDB (H) algorithms, were compared with a group of sequences from experienced patients. For certain thymidine analog mutations, concordance was found only two-thirds of the time for these interpretations, 45 and partial discordance was found almost one-third of the time. For example, each system can be assigned as a S (sensitive), I (intermediate), or R (resistant) value to mutations for three NRTI drugs. There are differences between the interpretation systems and discrepancies in resistance to NRTIs, even looking at common and familiar patterns of NRTI resistance. Respected expert systems do not agree whether there is a sensitive, intermediate, or resistant virus when predicting ABC susceptibility in the context of M184V genotypes, including 41, 184, and 215, which is probably one of the more common patterns of TAMs plus 184. Interpretation of genotype in common combinations of NRTI resistance mutations yields considerable differences as shown in Figure 4 .
A recent publication in AIDS examined the ACTG 364 study. 46 This was a rollover of ACTG 302 and ACTG 303 of patients who were started in the early 1990s on NRTIs. In addition to new dual NRTI regimens, they were randomized to nelfinavir (NFV), efavirenz (EFV), or both.
We recently reported a retrospective analysis of ViroLogic's phenotyping on these patients. The patients' most recent cut-offs and threshold susceptibility levels were used to define whether their drugs were likely to be active or partially active, or whether virus was completely resistant. Interpreting phenotype and assigning cut-offs in three-and four-drug regimens received by patients in ACTG 364, as either resistant or sensitive, required a dichotomous PSS of one or zero. The primary data show the wide divergence in resistance to each of the available ARV medications among 150 patients ( Figure 5 ).
With ZDV, there was a great spread of resistance across many-fold log changes. There was "hypersensitivity" shown to the non-nucleoside reverse transcriptase inhibitors (NNRTIs), which can predict virologic success. 46 However, we asked whether retrospective phenotype and modeling of virologic response could predict longterm clinical outcomes. We then assigned these PSSs as dichotomous and as continuous values, depending on the actual fold change. We asked what is the number of active drugs that needed to be included in a regimen, and whether sensitivity at baseline really predicts long-term virologic activity of drug regimens. The results are shown as a Kaplan-Meier analysis in Figure 6 .
Although all patients received at least three drugs, about 80 percent of them failed virologically within the first six months if the PSS was less than two. A PSS between two and three shows a gradual stepwise failure, which indicates slow breakthrough and evolution of resistance. If the PSS was greater than three, there was more durable suppression over three years. The kind of susceptibility testing needed to design a regimen will require careful modeling of the susceptibility of a patient's virus to the number of drugs, and choosing sufficient drugs for adequate potency. Currently, asking whether resistance tests are useful in the identification of active drugs depends on understanding limitations and uncertainties. Susceptibility is a continuum. For many of the drugs that we now use, there are no sharp cut-offs for resistance. We are still uncertain as to how much predicted activity is enough to include a drug in the regimen, and how much resistance is enough to warrant exclusion. There are many limits of resistance testing, and in the words variously attributed to Yogi Bera, Niels Bohr, or Dan Quayle, "It's very difficult to make predictions, particularly about the future." ■
